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Long Non Coding RNA MALAT1 
Promotes Tumor Growth and 
Metastasis by inducing Epithelial-
Mesenchymal Transition in Oral 
Squamous Cell Carcinoma
Xuan Zhou1,*, Su Liu1,*, Guoshuai Cai2,*, Lingping Kong1,*, Tingting Zhang3, Yu Ren4, 
Yansheng Wu1, Mei Mei4, Lun Zhang1 & Xudong Wang1
The prognosis of advanced oral squamous cell carcinoma (OSCC) patients remains dismal, and 
a better understanding of the underlying mechanisms is critical for identifying effective targets 
with therapeutic potential to improve the survival of patients with OSCC. This study aims to 
clarify the clinical and biological significance of metastasis-associated long non-coding RNA, 
metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in OSCC. We found that MALAT1 
is overexpressed in OSCC tissues compared to normal oral mucosa by real-time PCR. MALAT1 
served as a new prognostic factor in OSCC patients. When knockdown by small interfering RNA 
(siRNA) in OSCC cell lines TSCCA and Tca8113, MALAT1 was shown to be required for maintaining 
epithelial-mesenchymal transition (EMT) mediated cell migration and invasion. Western blot and 
immunofluorescence staining showed that MALAT1 knockdown significantly suppressed N-cadherin 
and Vimentin expression but induced E-cadherin expression in vitro. Meanwhile, both nucleus and 
cytoplasm levels of β-catenin and NF-κB were attenuated, while elevated MALAT1 level triggered 
the expression of β-catenin and NF-κB. More importantly, targeting MALAT1 inhibited TSCCA 
cell-induced xenograft tumor growth in vivo. Therefore, these findings provide mechanistic insight 
into the role of MALAT1 in regulating OSCC metastasis, suggesting that MALAT1 is an important 
prognostic factor and therapeutic target for OSCC.
Head and neck squamous cell carcinoma (HNSCC) is one of the most prevalent tumors in the world with 
over 500,000 cases diagnosed annually. Oral squamous cell carcinoma (OSCC), a subset of HNSCC, is 
characterized by a high risk of lymphnode metastasis and local invasiveness1. Despite of radical surgery 
combined with radiation, chemotherapy and targeted therapy, OSCC has a 5-year survival rate of about 
50%2. Thus, it’s urgent to find notable prognostic factors or metastatic predictors and therapeutic targets 
in OSCC.
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Epithelial-mesenchymal transition (EMT) endows metastatic properties upon cancer cells to promote 
migration, invasion, and subsequent dissemination and it is mainly characterized by loss of E-cadherin 
expression3,4. Up to now, it is unclear which subpopulation of OSCC patients will develop lymph-
node or distant metastasis. Recent researches indicate that multiple factors, including NF-κ B5, conical 
Wnt/β -catenin6, PI3K/Akt7, and EGFR signaling pathways8 may regulate the EMT process and mediate 
metastasis cascade in cancer cells.
Long noncoding RNAs (lncRNAs) are a class of non-protein coding transcripts longer than 200 nucle-
otides. Although increasing evidence describes lncRNAs as notable molecular markers involved in regu-
lating gene expression and cancer progression, our understanding of its role in cancer metastasis is very 
limited9,10. Recently several lncRNAs are validated to be associated with cancer metastasis and regulated 
by oncogenic or tumor suppressor pathways10. Metastasis-associated lung adenocarcinoma transcript 
1 (MALAT1), a highly conserved mammals’ lncRNA, is the transcript of noncoding nuclear-enriched 
abundant transcript 2 (NEAT2),and is specifically retained in nuclear speckles to modify pre-mRNA pro-
cessing11. MALAT-1 was first identified as prognostic parameters for patient survival in stage I non-small 
cell lung cancer (NSCLC)12. Recent researches suggest that MALAT1 level is positively correlated with 
clinical stages and serves as an oncogene in esophageal squamous cell carcinoma13, glioma14, renal cell 
carcinoma15and etc. Mechanistic investigations showed that MALAT1 was transcriptionally activated by 
c-Fos or Sp1 in renal cell carcinoma and lung cancer cells15,16. Another post-transcriptional regulation 
mechanism of MALAT1 by miR-101 and miR-217 exists in ESCC cells and this post-transcriptional 
silencing of MALAT1 could significantly suppress the proliferation of ESCC cells through the arrest of 
G2/M cell cycle17. MALAT1 has been shown to regulate some metastasis-associated genes in colon can-
cer, non-small cell lung cancer (NSCLC), glioma, and myeloma11,18,19. However, the role of MALAT1 in 
mediating the metastasis of OSCC has not been well investigated.
In the current study, by using gain- or lose-of-function assays, we validated that MALAT1 contributed 
to EMT-mediated metastasis in OSCC by modulating the activation of β -catenin and NF-κ B pathways.
Results
MALAT1 overexpression was associated with poor prognosis in OSCC. Post-surgery patho-
logical diagnosis indicated that, 10 of the 54 OSCC cases were well-differentiated, 20 cases were mod-
erately differentiated and 24 cases were poorly differentiated tumors. First, we defined the MALAT1 
expression status in all the 54 OSCC samples and 10 non-tumor normal oral mucosa samples. QPCR 
data indicated that MALAT1 expression in tumor (8.318 ± 0.88) is higher than in the normal mucosa 
samples (4.413 ± 0.757) (P < 0.05, Fig. 1a). No statistical difference in MALAT1 expression was detected 
by tumor differentiation status (data not shown). Second, according to the median MALAT1 expression, 
we divided the 54 OSCC cases into high and low MALAT1 expression groups. Kaplan-Meier survival 
analysis showed that patients with low MALAT1 expression (n = 35) had significantly increased overall 
survival compared with patients with high MALAT1 expression (n = 19, P < 0.05; Fig. 1b).
Inhibition of MALAT1 attenuated OSCC invasion and migration in vitro. We measured the 
MALAT1 expression in Tscca, Tca8113P160, Tca8113, Hep-2 and Tb3.1 cells by qPCR. Tca8113 and Tscca 
OSCC cells showed higher expression levels of MALAT1 than the other 3 cell lines(P < 0.05, Fig.  2a).
Thus, we chose Tca8113 and Tscca for further studies. In order to determine inhibition of MALAT1 might 
suppress OSCC cell invasion and migration in vitro, we transfected Tca8113 and Tscca OSCC cells with 
MALAT1 siRNA and a negative control oligonucleotide. At 24h, 48h and 72h after transfection, there was 
a significantly decrease of MALAT1 expression in both cell lines (P < 0.05, Fig. 2b). As indicated by the 
wound-healing assay, MALAT1 knockdown inhibited Tca8113 and Tscca cell migration ability compared 
Figure 1. Expression of MALAT1 in human oral squamous cell carcinoma. (a) MALAT1 was 
overexpressed in 54 OSCC samples (P < 0.05). (b) Kaplan–Meier survival curve analysis indicated that 
OSCC patients with lower MALAT1 expression had prolonged survival time compared with patients with 
high levels of MALAT1 (log-rank test, P < 0.05).
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with negative control or scramble transfected cells (P < 0.05, Fig. 2c,d). The transwell assay with matrigel 
(P < 0.05, Fig. 2e,f) or without matrigel (P < 0.05, Fig. 2g,h) revealed that in MALAT1 knockdown cells, 
invaded Tca8113 and Tscca cell numbers decreased significantly.
Overexpression of Matrix metalloproteinases (MMP-2/9) were believed to represent a strong invasion 
capability by degrading extracellular matrix (ECM) in cancer cells. Tissue inhibitors of tissue inhibitors 
of metalloproteinases (TIMPs) control MMP activities to minimize matrix degradation20,21. To further 
validate the role of MALAT1 in modulating OSCC invasion, we measured the expression levels of MMP-
2, MMP-9 and TIMP-3. As shown in Fig. 2i, Tca8113 and Tscca OSCC cells displayed suppressed MMP-
2/9 and VEGF expression but upregulated TIMP-3 expression after MALAT1 knockdown(P < 0.05). 
These results confirmed that MALAT1 inhibition downregulated MMP2/9 expression, and suppressed 
OSCC cell invasion and migration in vitro.
Inhibition of MALAT1 suppressed OSCC EMT in vitro. Previous studies have established that 
EMT is required for metastasis in multiple human epithelium cancers. Consequently, we measured EMT 
markers by western blot to evaluate whether MALAT1 could promote EMT-mediated OSCC invasion. 
Figure 2. Inhibition of MALAT1 attenuated OSCC invasion and migration in vitro. (a) Tscca and 
Tca8113 cells displayed highest expression levels of MALAT1 among the HNSCC cell lines. (b) MALAT1 
siRNA transfection inhibited effectively MALAT1 expression in Tscca and Tca8113 cells (P < 0.05). (c,d) 
MALAT1 siRNA significantly inhibited Tscca and Tca8113 cell migration determined by wound healing 
assay (P < 0.05). (e,f) MALAT1 siRNA significantly inhibited Tscca and Tca8113 cell migration and invasion 
determined by transwell assays with matrigel (P < 0.05). (g,h) MALAT1 siRNA significantly inhibited Tscca 
and Tca8113 cell migration determined by transwell assays without matrigel (P < 0.05). (i) MALAT1 siRNA 
significantly inhibited the expression of MMP2/9, and VEGF, but increased the expression of TIMP-3 in 
Tscca and Tca8113 cells determined by western blots analysis (P < 0.05). The gels were crapped, but those 
gels were run under the same experimental condition.
www.nature.com/scientificreports/
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Specifically, loss-of-function of E-cadherin was believed to initiate EMT and human cancer metastasis22. 
In Tca8113 and Tscca cells, MALAT1 silencing induced E-cadherin by 2.65–6.65 folds (P < 0.05), and 
suppressed N-cadherin by 1.79–2.17 folds (P < 0.05) comparing to negative control and scramble cells 
(Fig. 3a). Similarly MALAT1 silencing suppressed Vimentin expression by 0.4–0.53 in both the two cell 
lines (P < 0.05, Fig. 3a). Moreover, notable transcription factors like Slug, Zeb-1 and Twist-1 expression 
were significantly inhibited in MALAT1 siRNA treated Tca8113 and Tscca cells (P < 0.05, Fig. 3a).
To further explore the effect of targeting MALAT1 on EMT, IF was employed to analyze the expres-
sion of epithelial and mesenchymal markers, as shown in Fig.  3b,c. Treatment of MALAT1 siRNA 
resulted in increased expression of E-cadherin, but decreased expression of Vimentin and N-cadherin, 
compared to that in control cells. We next examined the morphological changes of F-actin, which was 
required for invadopodia formation23. In negative control and scramble OSCC cells, F-actin presented a 
strong cortical pattern, suggesting mesenchymal features and high movement capability (Fig. 3b). While 
Figure 3. Inhibition of MALAT1 suppressed EMT in OSCC in vitro. (a) MALAT1 siRNA significantly 
increased the expression of E-cadherin and inhibited the expression of N-cadherin, ZEB1, Vimentin, Slug, 
and Twist-1 in Tscca and Tca8113 cells determined by western blots analysis(P < 0.05). The gels were 
crapped, but those gels were run under the same experimental condition. (b) F-actin staining showed a 
stress-fiber pattern in control or NC siRNA treated cells, whereas a cortical pattern in MALAT1 siRNA-
treated cells by immunofluorescence staining. (c) MALAT1 siRNA significantly upregulated E-cadherin and 
downregulated N-cadherin and Vimentin in Tscca and Tca8113 cells determined by immunofluorescence 
staining (original magnification: 1000× ).
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in MALAT1 siRNA treated cells, F-actin presented relative stress fiber pattern, suggesting significantly 
inhibitory effect on mesenchymal features and cell movement capability. Taken together, these data indi-
cated that MALAT1 silencing could dramatically affect the EMT and rearrangement of cytoskeletal pro-
teins in OSCC cells in vitro.
Inhibition of MALAT1 reduced the activation of β-catenin and NF-κB signaling pathways in 
OSCC. Since β -catenin and NF-κ B pathways were reported to be the key regulators in EMT, we con-
sequently explored whether MALAT1 gain- or loss- of function could mediate EMT in OSCC through 
β -catenin and NF-κ B pathway. We measured whether MALAT1 knockdown could affect β -catenin tran-
scriptional activity by the TOP flash reporter assay. Compared with negative control and scramble cells, 
remarkably decreased activity of the β -catenin/TCF4 was observed in both MALAT1 siRNA treated 
Tca8113 and Tscca cells (P < 0.05, Fig. 4a). Whole cell lysate analysis indicated that β -catenin and phos-
phorylated β -catenin level were decreased in both cell lines (P < 0.05, Fig. 4b). Additionally, NF-κ Bp65, 
the activation form of NF-κ B, displayed a decreased expression level in MALAT1 siRNA treated OSCC 
cells (P < 0.05, Fig.  4b). Cell components of protein analysis indicated that β -catenin, p-β -catenin and 
NF-κ Bp65 were suppressed significantly in nucleus and cytoplasm (P < 0.05, Fig.  4c,d). To further 
validate the effect of MALAT1 on β -catenin and NF-κ B, we introduced MALAT1 expression vector 
Figure 4. Inhibition of MALAT1 reduced the activity and level of β-catenin and NF-κB in OSCC. (a) 
A TOP flash reporter assay indicated that MALAT1 siRNA treatment inhibited β -catenin transcriptional 
activity in Tscca and Tca8113 cells (P < 0.05). (b) MALAT1 siRNA treatment inhibited β -catenin, 
p-β -catenin and NF-kBp65 expression in whole cell lysate of Tscca and Tca8113 cells (P < 0.05). (c) 
MALAT1 siRNA treatment inhibited β -catenin, p-β -catenin and NF-kBp65 expression in nucleus lysate 
of Tscca and Tca8113 cells (P < 0.05). (d) MALAT1 siRNA treatment inhibited β -catenin, p-β -catenin and 
NF-kBp65 expression in cytosol lysate of Tscca and Tca8113 cells (P < 0.05). (e) PCDNA3-MALAT1 vector 
transfection increased MALAT1 expression in Hep-2 cells with a relative low level of MALAT1 expression 
(P < 0.05). (f) PCDNA3-MALAT1 vector transfection increased the expression of β -catenin, p-β -catenin and 
NF-kBp65 in whole lysate of Hep-2 cells (P < 0.05). The gels were crapped, but those gels were run under 
the same experimental condition.
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(pCDNA-MALAT1) into Hep-2 cells that had a low endogenous MALAT1 expression level as shown 
in Fig.  2a. Consequently, comparing with control and pCDNA-NC group, pCDNA-MALAT1 treated 
Hep-2 cells showed increased MALAT1 mRNA level since 24 h after transfection(P < 0.05, Fig.  4e). 
Western blots analysis indicated that β -catenin, p-β -catenin and NF-κ Bp65 were increased significantly 
in pCDNA-MALAT1 Hep-2 cells(P < 0.05, Fig.  4f).We next employed the wound-healing assay and 
transwell assay to further assess the changes of invasion or migration ability by introducing MALAT1 
into Hep-2 cell. Wound-healing assay indicated that, pCDNA-MALAT1 transfected Hep-2 cell displayed 
increased wound healing speed comparing with the control cells(P < 0.05, Supplementary Figure 1a,b). 
The transwell assay with matrigel revealed that in Hep-2 cells after transfection, invaded cell numbers 
increased significantly(P  < 0.05, Supplementary Figure 1c,d). We also used measured western blot to 
evaluated the changes of EMT markers expression in Hep-2 cell with pCDNA-NC or pCDNA-MALAT1 
transfection, The results shown that N-cadherin, Vimentin, Slug, MMP-9 and VEGF expression were all 
upregulated significantly (P < 0.05, Supplementary Figure 1e).These data suggested that MALAT1 might 
involve in regulating β -catenin and NF-κ B signaling pathways in OSCC.
Inhibition of MALAT1 suppressed tumor growth in Tscca xenograft model. To further verify 
the role of MALAT1 and to determine the therapeutic potential of targeting MALAT1 in OSCC, we 
established xenograft tumor models using Tscca cell lines. The tumor weight and tumor growth curve 
suggested that, MALAT1 inhibition suppressed effectively tumor growth comparing with the control and 
scramble treated xenograft tumors (P < 0.05, Fig.  5a–c). Suppressed Ki67 and MMP2/9 expression by 
IHC in MALAT1 siRNA treated Tscca tumors suggested the tumor cell proliferation and ECM degrada-
tion capability were inhibited significantly (P < 0.05, Fig. 5d).And EMT markers including N-cadherin 
and Vimentin were suppressed in MALAT1 siRNA treated Tscca tumors (P < 0.05, Fig.  5d). Because 
MALAT1 might promote OSCC tumor growth in vivo, it may serve as a therapeutic target for treatment.
Discussion
Recent integrated genomic analysis indicated that abnormal expression of lncRNAs contributes to human 
carcinogenesis, metastasis, stem cell differentiation, and resistance to chemotherapy or radiation. Generally 
speaking, lncRNAs, like HOTAIR, function as a scaffold tool to recruit target chromatin-modifying com-
plexes to specific chromatin sites24. For example, HOTAIR acts as an onco-lncRNA by recruiting PRC2 
complex to catalyze H3K27 triple methylation and thus inhibits transcription of downstream tumor 
suppressor genes25. Targeting HOTAIR could inhibit tumor growth of glioblastoma26, breast cancer27 
and other cancers28. Similarly, MALAT1 is overexpressed in many malignancies, including esophageal 
squamous cell carcinoma13, glioblastoma29, breast cancer30, and prostate cancer31. These findings suggest 
MALAT1 may be an oncogene. In this study, we provided both experimental and clinical evidence to 
support MALAT1 as a cancer metastasis related molecule and a potential therapeutic target in OSCC.
We validated that MALAT1 was overexpressed in OSCC tumor samples compared with the normal 
oral mucosa samples, and MALAT1 over-expression confers a shorter survival. Tang H et al. reported 
that no statistical significance of MALAT1 expression was determined in a small OSCC sample32. 
Interestingly, a recent meta-analysis reported that MALAT1 overexpression was correlated with a poor 
overall survival and the pooled hazard ratio (HR) and corresponding 95% confidence interval (CI) was 
1.94 (95% CI 1.59–2.38) in 792 cancer patients33. Thus, we believe MALAT1 is a potential prognostic 
factor in human cancers including OSCC.
Immerging evidence has shown that MALAT1 contributes to cancer invasion and metastasis. In 
normal cells, MALAT1 interacts with several pre-mRNA splicing factors, such as serine/arginine (SR) 
splicing factors, and influences alternative splicing of pre-mRNAs by regulating the distribution and 
activity of SR splicing factors. In colorectal cancer, MALAT1 could disturb the stability of SFPQ/PTBP2 
complex, and promote cell proliferation and migration34. Shen L reported that MALAT1 could be used 
as predictor of NSCLC brain metastasis and outcome and MALAT1 promoted brain metastasis of lung 
cancer by inducing EMT in H1915 cells35. MALAT1 can also activate MAPK-ERK signaling to affect cell 
proliferation and metastasis in gallbladder carcinoma36.
Increasing concentration of cisplatin and paclitaxel treatment could suppress the expression of lncRNAs 
(CDKN2B-AS1, HOTAIR and MALAT1) in laryngeal Hep-2 cells37. These findings indicate that MALAT1 
is associated with cancer progression by regulating multiple signaling pathways. We proved that MALAT1 
knockdown Tca8113 and Tscca cells displayed decreased migration and invasion in vitro. Accordingly, the 
degradation of extracellular matrix was reduced, conferred by down regulation of MMP-2/9 and up regu-
lation of TIMP-3.
NF-κ B and β -catenin are believed to be oncogenes that contribute to tumor proliferation and 
metastasis in many human cancers. For instance, constitutively active p65 subunit of NF-κ B inhibited 
E-cadherin expression by stimulating ZEB-1/2 transcription38. Consequent activation of ZEB-1/2 pro-
motes EMT and metastasis. Abnormal activation and nuclear translocation of β -catenin can stimulate 
gene expression and production of proteins involved in cell transformation by binding to LEF-1/TCF 
family39. Active form of β -catenin stimulates MMPs and VEGF expression to promote cancer invasion 
and angiogenesis40. Our data showed that MALAT1 knockdown cells displayed decreased nuclear accu-
mulation of NF-κ Bp65, β -catenin and p-β -catenin.
www.nature.com/scientificreports/
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Figure 5. MALAT1 knockdown inhibited tumor growth in a xenograft model in vivo. (a) The image 
of Tscca xenograft tumors treated with si-NC and si-MALAT1. (b) Tumor growth curve indicated that 
MALAT1 siRNA injection treatment inhibited significantly Tscca xenograft tumor growth (P < 0.05). 
(c) Average tumor weight of si-MALAT1 group was reduced compared to the control and si-NC groups 
(P < 0.05). (d) IHC staining showed the expression of Ki-67, MMP-2, MMP-9, N-cadherin and Vimentin 
were inhibited in the MALAT1 siRNA-treated Tscca xenograft tumors (original magnification: 200× ).
www.nature.com/scientificreports/
8Scientific RepoRts | 5:15972 | DOi: 10.1038/srep15972
In summary, we demonstrated MALAT1 as an important oncogene like other lncRNAs in OSCC 
and its expression frequently is upregulated in human tumor samples and cancer cell lines. Functionally, 
MALAT1 promoted cell migration and invasion via regulating nuclear translocation of NF-κ B and 
β -catenin, and subsequently EMT in OSCC. Further investigation into the molecular mechanism under-
lying dysregulation of MALAT1 expression in OSCC cells will help to better understand tumor pro-
gression of OSCC, identify candidate biomarkers for OSCC prognosis, and guide the development of 
therapeutic targets for oral cancer.
Methods
Tissue samples. A total of 54 OSCC tumor samples from radical resection were randomly collected at 
Tianjin Medical University Cancer Institute & Hospital during January 2009 to December 2010. Twelve 
non-tumor normal oral mucosa samples were obtained from Tianjin Medical University Stomatological 
Hospital. The demographic and clinical data was collected from electric records. All the tissue sam-
ples were used for MALAT1 expression examination. All samples were collected with informed consent 
according to the Internal Review and Ethics Boards of the Tianjin Medical University Medical Ethnic 
Committee.
Cell culture and transfection. Human tongue squamous cell carcinoma cell lines Tscca, Tca8113P160, 
Tca8113 and Hep-2 were purchased from the Institute of Basic Medical Sciences, Chinese Academy 
of Medical Sciences. Tb3.1 cell line was a gift from the Ninth People’s Hospital Shanghai Jiao Tong 
University. The cell lines were maintained in MEM or RPMI-1640 (Thermo Scientific, USA) supple-
mented with 10% fetal bovine serum (FBS, Thermo Scientific, USA)with 5% CO2 at 37 °C.
RNA extraction and qPCR. Total RNA was extracted by using Trizol (Life technology, USA) reagent 
according to the manufacture’s protocol and reversely transcribed into cDNA using M-MLV Reverse 
Transcriptase (Life technology, USA). RT-qPCR was performed using Step One Plus system (Applied 
Biosystems, USA). The primer of MALAT1 was “GACGGAGGTTGAGATGAAGC” (Forward) and 
“ATTCGGGGCTCTGTAGTCCT” (Reverse) (Life technology, USA). The RT-qPCR procedure was per-
formed under the following conditions: 5 min at 95 °C followed by 40 cycles of 10 sec at 95 °C and 45 sec 
at 60 °C41. All MALAT1 expression data were normalized to GAPDH from the same sample. The Ct 
value of each target gene was normalized against the Ct value of the reference gene (Ct (MALAT1)—Ct 
(GAPDH)).
MALAT1 siRNAs transfection. Double-stranded siRNAs (Sigma-Genosys, USA) were used to 
knockdown MALAT1 from cells at a final concentration of 20 μ mol/L.
Vector transfection. 10 μ g MALAT1 full-length expression vector (FulenGen, China) was transfected 
to 2 × 106 OSCC cells by using Lipofectamine3000 reagent as the manufacturer’s instructions (Invitrogen, 
USA). The PGL-3 empty vector was used as the control plasmid. 72 hr after transfection, total RNA and 
cell lysate were collected for qPCR and Western blot analysis.
Western blot analysis. The MALAT1 knockdown cells were washed twice with ice-cold PBS and 
treated with lysis buffer (Solarbio, China) or nuclear and cytoplasmic extraction reagent kit (Beyotime, 
China). Heat-denatured protein samples (25 μ g per lane) were resolved by SDS poly-acrylamide gel 
electrophoresis (PAGE) and transferred to an Immobilon-P membrane (Millipore, Bedford, MA). The 
membrane was incubated with primary anti-body overnight at 4 °C, 1 h with a secondary antibody at 
room temperature, followed by ECL reagent (Millipore, Bedford, MA) for chemiluminescent detection. 
Primary antibody of MMP-2/9, TIMP-3, VEGF, Twist-1, GADPH (Santa Cruz, CA), E/N-cadherin, 
Zeb-1, Vimentin, Slug, β -catenin/-p and NF-κ Bp65 (Abcam, UK) were used for WB analysis.
Wound healing assay. A total of 10,000 Tscca or Tca8113 cells were plated in 6-well plates. When 
cells grew to confluence at 80%, inserts were then removed with sterile forceps to create a wound by 
using a 200 μ l tip. After removing the cellular debris with PBS, cells were exposed to PBS, Scramble and 
MALAT1 siRNA for 48 h. Cell migration were perceived by inverted microscope and photographed. The 
wound area was scaled by Image Pro Plus 5.0 (Olympus, Japan).
Transwell assay. Cell invasion assay was performed using transwell membranes coated with Matrigel 
(BD Biosciences). Transfected cells were plated at a density of 3 × 104 cells per well. The lower chamber 
was filled with 20% FBS. After 48 h, cells remaining in the upper chamber were removed with cotton 
swabs, while invading cells were fixed with 4% paraformaldehyde (Santa Cruz, USA), stained with crystal 
violet (Solarbo, China).
Immunofluorescence staining (IF). For IF study, MALAT1 knockdown and control cells were 
incubated with primary antibodies (1:200 dilutions) overnight at 4  °C, followed by incubated with 
FITC-labeled secondary antibody (1:100 dilutions, Santa Cruz, CA) for 1 h at room temperature. Nuclei 
www.nature.com/scientificreports/
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were counterstained with DAPI reagent (Life technology, USA). Positive cells were visualized using 
FV-1000 laser scanning confocal biological microscopes (Olympus, Japan).
Tscca xenograft tumor model. All animal protocols were approved by Tianjin Medical University 
Animal Care and Use Committee. The female, SPF grade Nu/Nu nude mice at age of 4 weeks (Vital River 
Laboratories, China) (n = 10 for each group) were implanted subcutaneously with 5 × 106 Tscca cells as 
described previously42. The tumor volume was measured with a caliper every 3 days using a formula 
(volume = long diameter × short diameter2/2). When the volume of xenograft tumor is approximately 
250 mm3, the tumor was injected with PBS (25 μ L, local injection) or MALAT1 siRNA (30 ng, local 
injection) every 3 days. After 3 weeks, the mice were sacrificed and the xenograft tumors were removed 
for formalin fixation and preparation of paraffin-embedded sections.
Immunohistochemistry (IHC). For IHC staining, paraffin-embedded tumor slides were deparaffin-
ized, rehydrated and incubated with primary antibodies overnight at 4 °C. The primary antibody against 
Ki-67, MMP2/9 (Santa Cruz, CA), N-cadherin and Vimentin (Abcam, UK) were used for detection. 
Then, they were incubated with biotin-labeled secondary antibody (ZhongshanBio Corp., China) for 1h 
at room temperature and incubated with diaminobenzidine (Zhongshan Bio Corp., China). The results 
were assessed by measuring both the staining intensity and the number of positive cells. The intensity 
of the positive reaction was scored, i.e. 0 = negative, 1 = weak, 2 = moderate, and 3 = intense staining. 
Additionally, staining was scored on a scale of 0–3 according to the percentage of the cells involved: i.e. 
0 = 0–5%; 1 = 6–25%; 2 = 26–50%; and 3 = 51–100% positive cells. The scores for the intensity and the 
percentage of positive cells were multiplied to work out at a weighted score for each case. A score of 0–3 
was defined as low expression (− ), and scores of 4–9 as high expression (+ ).
Statistical Analysis. Data was expressed as means ± S.E. Statistical analysis was performed by 
ANOVA, χ 2 test, or Student’s t-test using SPSS18.0 software. Statistical significance was determined as 
a P < 0.05 (*).
Ethics Statement
Methods used in this study were carried out in accordance with the approved guideline of the Tianjin 
Medical University Medical Ethnic Committee. All subjects provided written informed consent for par-
ticipation in this study and a review of their medical records, and provided a sample of tumor tissue 
sample. We clarified that all the procedures by using the human tissues, including colleting the tis-
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